URGN

UroGen Pharma Ltd. URGN

NasdaqSmall CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,461 of 2,925

Why it scores 31Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$72.46M

Quarter to Jun 30

Net income

$-14.35M

Quarter to Jun 30

Free cash flow

$-33.07M

Quarter to Jun 30

Operating margin

0.1%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.56B total
RTW INVESTMENTS, LP
$167.22M0.0%
BlackRock, Inc.
$117.81M+12.5%
MORGAN STANLEY
$94.81M+0.6%
Kynam Capital Management, LP
$89.58M+8.3%
LEUCADIA NATIONAL CORP
$80.95M0.0%
SG Americas Securities, LLC
$75.55M+23.8%
AMERICAN CENTURY COMPANIES INC
$62.03M+2.9%
ACORN CAPITAL ADVISORS, LLC
$61.58M0.0%
Point72 Asset Management, L.P.
$56.14MNew
FRONTIER CAPITAL MANAGEMENT CO LLC
$55.51M+14.8%
Opaleye Management Inc.
$52.99M+0.7%
SILVERARC CAPITAL MANAGEMENT, LLC
$47.91M-13.4%
MENORA MIVTACHIM HOLDINGS LTD.
$42.41M0.0%
D. E. Shaw & Co., Inc.
$42.17M+12.0%
STATE STREET CORP
$36.91M+14.7%
MPM BioImpact LLC
$34.35M-1.1%
Soleus Capital Management, L.P.
$30.54M+14.1%
GOLDMAN SACHS GROUP INC
$30.17M+37.0%
Migdal Insurance & Financial Holdings Ltd.
$28.37M0.0%
ORBIMED ADVISORS LLC
$24.88M-22.8%
GEODE CAPITAL MANAGEMENT, LLC
$22.46M+16.5%
Woodline Partners LP
$18.43M0.0%
Boxer Capital Management, LLC
$18.40M0.0%
BANK OF AMERICA CORP /DE/
$17.51M+275.2%
VANGUARD PORTFOLIO MANAGEMENT LLC
$16.80M+11.5%
See all 191 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/URGN

Loading ratio trend…

URGN key financials by period

Reported revenue, net income and operating margin by fiscal year, from UroGen Pharma Ltd.'s annual filings on SEC EDGAR.

UroGen Pharma Ltd. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$109.8M$-153.5M-113.7%
FY 2024$90.4M$-126.9M-107.1%
FY 2023$82.7M$-102.2M-79.2%
FY 2022$64.4M$-109.8M-122.8%
FY 2021$48.0M$-110.8M-192.1%
FY 2020$11.8M$-128.5M—
Source: URGN filings on SEC EDGAR →

Companies similar to URGN

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

URGN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About UroGen Pharma Ltd. (URGN): stock profile, AI score and financials

UroGen Pharma Ltd. (URGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores URGN at 30.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,461 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), UroGen Pharma Ltd. reports quarterly revenue of $72.5M, net income of $-14.4M, an operating margin of 0.1%. Top institutional holders of URGN by reported 13-F value include RTW INVESTMENTS, BlackRock, MORGAN STANLEY, based on the most recent SEC filings. URGN trades on the Nasdaq exchange and files with the SEC under CIK 1668243. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate URGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for UroGen Pharma Ltd. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1668243 →